Home / News / Orthofix launches VersaShield, a natural wound covering

Orthofix launches VersaShield, a natural wound covering

01 Nov '12

1 min read

Orthofix International N.V. announced the introduction of VersaShield, a naturally physiologic wound covering for use in both spinal and orthopedic applications. This amniotic allograft tissue form is processed by The Musculoskeletal Transplant Foundation, or MTF.

In further collaboration with MTF, we are also excited about our launch next year of Trinity Elite, which is the next generation our highly successful Trinity Evolution.

Bruce Stroever, CEO of MTF commented, "For more than a century, doctors have used amniotic tissue for a broad variety of clinical applications in such fields as General Surgery, Dental, Ob/Gyn, Ocular Surgery, Spine and Sports Medicine.

This is due to the beneficial anti-inflammatory, anti-adhesive, anti-microbial, and non-immunogenic properties of the tissue graft. MTF is pleased to continue our partnership with Orthofix on the introduction of VersaShield amniotic membrane in order to make innovative biologic solutions available to all spine and orthopedic surgeons."

VersaShield is an allograft tissue processed from placental tissue recovered from living donors during healthy child births. VersaShield can be stored at room temperature and possesses easy handling characteristics. It will be distributed by our spine and orthopedic distribution networks.

Orthofix International N.V.